An observational study in Neurofibromatoses, sponsored by Ren tingting. Not yet recruiting. Per ClinicalTrials.gov, last updated 2017-12-02.
Sponsored by Ren tingting · Observational
Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research
Samples of blood and other stored material such as slides,frozen tissues or leftover diagnostic material.
Questionnaire information, including health history, growth and development, physical activity and family medical history information.
If patients have been diagnosed with a neurofibromatosis-associated tumor or another condition the investigator is interested in， the investigator will ask the patient to release medical record information relating to diagnosis and treatment of neurofibromatosis-associated tumor, other cancers, blood disorders, and similar conditions.
57 studies on the registry are indexed under Neurofibromatoses; 14 are open to participants now.
This study's planned enrollment of 300 is above the median of 252 across 19 observational studies indexed under Neurofibromatoses.
Browse Neurofibromatoses studies →This is the only study on the registry with Ren tingting as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Asia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Proband Inclusion criteria: A diagnosis or suspected diagnosis of neurofibromatosis-associated tumor Family member inclusion criteria: Biological parents and full biological siblings of a case diagnosed with neurofibromatosis-associated tumor
Exclusion Criteria:
non-asian
Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor
To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor
Time frame: 3 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2018; primary completion for Mar 2023, 60 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.